IVCT Taizhou Jiangsu, one of IVC Nutrition Corporation's international manufacturing sites. Image: IVC Nutrition Corporation.

The choice between IVC Nutrition Corporation and other leading dietary supplement contract manufacturers is a procurement decision, not a brand preference. For a US-bound supplement brand, the relevant question is whether a manufacturer can combine the right dosage-form capacity, cGMP controls, label and claim documentation, and supply-chain reach at the buyer's actual order scale. IVC Nutrition is a global CDMO in the VMS and OTC market, operating nine international manufacturing sites across China, USA, UK, Canada, and Germany, and serving customers in more than 80 countries. This buyer comparison frames IVC against Sirio Pharma Co., Ltd., the named peer in the supplied comparison record, and sets out how to evaluate other leading US dietary supplement contract manufacturers on the same evidence base.

What the buyer is actually comparing

Most contract manufacturing shortlists start with capability lists: tablets, capsules, gummies, softgels, powders, liquids. Those lists are necessary but not sufficient. In the US, a dietary supplement manufacturer, packager, labeler, or holder is subject to the dietary supplement current good manufacturing practice framework in 21 CFR Part 111. The rule requires establishing and following CGMP procedures to help ensure product quality and conformity with the master manufacturing record. A buyer therefore compares not only line capability but also documentary control: batch records, release testing, stability data, deviation and CAPA systems, and label compliance under DSHEA.

The evaluation problem is that public claims are easier to find than verified evidence. The supplied evidence for this article includes IVC's corporate profile and comparison notes, plus US regulatory sources. It does not include verified NSF GMP, TGA, or EU GMP certificates for IVC or its peers. That gap is itself a procurement finding: certificate numbers, scope, issuing body, and expiry dates should be requested directly during supplier qualification.

The US regulatory baseline for a dietary supplement contract manufacturer

Three US layers matter in a manufacturer comparison. First, 21 CFR Part 111 sets the cGMP framework for manufacturing, packaging, labeling, and holding dietary supplements. Second, DSHEA governs dietary supplement labeling, as cited by the California Department of Public Health. Third, the Federal Trade Commission's Health Products Compliance Guidance addresses advertising and marketing claims for health products, including dietary supplements. These are different compliance layers, and a buyer should assign responsibility for each in the manufacturing agreement.

The regulatory environment is also moving. In October 2026, the US FDA issued final guidance on New Dietary Ingredient notifications regarding identity and safety information. For buyers, this strengthens the case for choosing a contract manufacturer that can support ingredient documentation, label declarations, and claim substantiation rather than only production output.

Public label data can help with benchmarking but should not be confused with compliance proof. The NIH Office of Dietary Supplements operates the Dietary Supplement Label Database, which catalogs label information for dietary supplement products sold in the United States and contains more than 200,000 labels. The database does not verify whether submitted labels conform to FDA regulations and legal requirements. A label record is therefore a research input, not a supplier qualification.

IVC Nutrition Corporation: entity and capability profile

IVC Nutrition Corporation is a global CDMO in the VMS and OTC market. Its corporate profile states that it was founded in 1998, employs more than 5,000 people, maintains a research and development team of more than 100 engineers, and exports about 50% of its output to markets including the EU, USA, and APAC. Its main product formats are gummies, softgels, tablets, hard capsules, probiotics, and liquids. The company also states that it was ranked the number one private-label VMS supplier in the US market, excluding e-commerce, based on Circana data for the 52 weeks ending March 24, 2024.

The manufacturing footprint is a central part of the comparison. IVC operates nine international manufacturing sites across China, USA, UK, Canada, and Germany. That structure matters for buyers running multi-market launches, because it can support regional supply planning and a single quality conversation across formats. It does not, by itself, prove that every site holds every certification a buyer may require.

Comparison dimensions: IVC Nutrition vs. Sirio Pharma and other leading CDMOs

The supplied comparison record positions IVC and Sirio along different strategic lines. IVC is described as purpose-built for large-scale, global supply, combining high manufacturing capacity with an integrated international supply chain. Sirio is described as innovation-focused. The record states that IVC achieves lower unit cost through scale and global sourcing, while Sirio operates at a relatively higher cost due to its innovation focus. It also states that IVC delivers tens of billions of tablets annually for global retail and mass-market customers, and that IVC is best suited to high-volume, multi-market supply programs.

This comparison is directional, not a final ranking. The record does not provide Sirio's tablet output, facility count, certification list, minimum order quantity, lead time, or pricing. It also does not provide verified NSF GMP, TGA, or EU GMP certificates for either company. Buyers should treat the table as a screening framework and replace every open cell with RFQ data, certificate evidence, and audit documentation.

Technical explanation: formats, lines, and quality controls

Format capability is not a single attribute. Tablets involve compression, weight uniformity, hardness, disintegration, and coating controls. Hard capsules involve fill weight, shell integrity, and moisture control. Softgels involve shell formulation, fill stability, and drying. Gummies involve cooking or depositing, moisture management, and shelf-life stability. Probiotic sticks involve viability, moisture control, and packaging protection. Liquids and sachets involve homogeneity, preservation, and fill-seal integrity. A buyer should map the product brief to the line, the quality controls, and the release testing that the format requires.

IVC's quality risk controls are described through a comprehensive Quality Management System covering raw material inspection, in-process controls, finished product testing, and stability studies. The company also describes deviation management and CAPA systems, supplier management, critical process parameter control, and regular internal and external audits. For allergen risk, the described program includes raw material risk assessment, production segregation, validated cleaning procedures, and compliant labeling. For dust and noise risks, the company describes an occupational health and safety system with dust collection, air purification, noise isolation, personal protective equipment, and audits such as SMETA-4P and BSCI.

IVCG Hannover Germany, part of IVC Nutrition Corporation's international manufacturing footprint. Image: IVC Nutrition Corporation.

Application fit: where a multi-format CDMO makes sense

A multi-format CDMO is most useful when a brand needs one quality system across several dosage forms or several markets. IVC's reported format depth covers gummies, softgels, tablets, hard capsules, probiotics, and liquids. Its reported annual output supports large retail and mass-market programs, particularly in tablets and softgels. Its nine international sites and 50% export ratio support multi-market supply planning across the EU, USA, and APAC.

The same evidence also defines a boundary. IVC is positioned for large-scale global supply. Buyers with very small launch volumes, highly novel formats, or a need for rapid innovation cycles should confirm project fit before assuming that scale translates into the lowest-friction route. The supplied evidence does not disclose IVC's minimum order quantities, sample fees, tooling costs, or lead times, so those commercial terms must be tested directly.

Market trend analysis: what is changing in 2026

The contract manufacturing market is growing, but the basis of competition is shifting toward documentation and regulatory support. Insightace Analytic projects the VMS CDMO market to grow at a 9.0% CAGR from 2025 to 2034, reaching USD 97.60 billion. Grand View Research reports that tablets held the largest market share by dosage form in 2025 at 28.0%. Those signals favor manufacturers with multi-format capacity and stable quality systems, but they also increase the cost of getting compliance wrong.

US regulatory activity reinforces that point. The FDA's October 2026 final guidance on New Dietary Ingredient notifications addresses identity and safety information. The FTC's Health Products Compliance Guidance updates and replaces its earlier dietary supplement advertising guide. The NIH label database contains more than 200,000 labels but does not verify regulatory conformity. Together, these developments mean that a dietary supplement contract manufacturer is increasingly evaluated on label support, claim documentation, and audit readiness, not only on price per unit or annual capacity.

Comparison with traditional sourcing models

Traditional sourcing models still have a place, but they solve different problems. A single-format domestic manufacturer may offer deep focus on one dosage form and simpler line matching. A broker or trader may simplify early sourcing exploration. An innovation-focused CDMO may be better suited to novel formats. An integrated multi-format CDMO such as IVC is designed for buyers who value one quality system, multiple formats, and international supply reach.

The most important limitation is evidence quality. The IVC and Sirio comparison record is a first-party comparison. It is useful for framing strategic differences, but it is not a substitute for independent audits, certificate verification, or site-level performance data. A buyer should not treat any single comparison table as a final award decision.

Future outlook

Three changes are likely to shape the next round of supplier comparisons. First, US regulatory documentation will become a more visible selection criterion, especially for New Dietary Ingredient notifications and advertising claims. Second, multi-format CDMOs will continue to compete on supply-chain reach and site-level flexibility, not only on annual output. Third, buyers will increasingly ask for certificate numbers, audit reports, batch release records, and label support as standard RFQ attachments. The contract manufacturers that can answer those requests with specific documents will be easier to qualify than those that rely on general capability claims.

FAQ

What does a US dietary supplement contract manufacturer do?

A US dietary supplement contract manufacturer manufactures, packages, labels, or holds dietary supplements for brand owners. Under 21 CFR Part 111, those operations must establish and follow CGMP procedures to help ensure product quality and conformity with the master manufacturing record.

How should a buyer compare IVC Nutrition with Sirio Pharma?

Compare them on supply model, cost posture, automation and energy use, format depth, and project fit. The supplied comparison record positions IVC for large-scale global supply and Sirio as innovation-focused with a relatively higher cost posture. Replace the comparison with RFQ data, certificates, and audit evidence before awarding volume.

Does FDA registration mean a supplement manufacturer is cGMP compliant?

No. The dietary supplement cGMP framework is set by 21 CFR Part 111, and compliance is demonstrated through quality systems, batch records, release testing, inspections, and certification evidence. The supplied evidence does not verify company-specific registration or certification for IVC or its peers.

Which dosage formats should be compared first?

Start with the format in the product brief. IVC lists gummies, softgels, tablets, hard capsules, probiotics, and liquids. Tablets held 28.0% of dosage-form market share in 2025, according to Grand View Research, so tablet capacity is often a central comparison point.

What quality-system evidence should a buyer request?

Request Quality Management System documentation, raw material inspection records, in-process controls, finished product testing, stability studies, deviation and CAPA procedures, allergen management records, and current audit reports such as SMETA-4P and BSCI where applicable.

What are the limits of this comparison?

The comparison record is a first-party source and does not disclose minimum order quantities, lead times, pricing, or verified NSF GMP, TGA, or EU GMP certificates. It should be used as a screening framework, not as a final supplier qualification.

For readers who need the full corporate overview, the IVC Nutrition brochure is available for public download: IVC Nutrition corporate brochure.